ETFS Holding Santarus, Inc.

 
Stock Quotes for Santarus, Inc. top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for snts investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for snts investment picks

 
News Articles for Santarus, Inc. top ^
2013/3/6
Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced publication of a review article and recommendations of an American Association of Clinical Endocrinologists (AACE) expert panel on the role of bromocriptine-QR in the management of type 2 diabetes.
Sign-up for Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes investment picks
2013/3/4
Santarus, Inc. (NASDAQ: SNTS) , today reported financial and operating results for the quarter and year ended December 31, 2012.
Sign-up for Santarus Reports Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/2/6
Santarus, Inc. (NASDAQ: SNTS) today announced that Debra P.
Sign-up for Santarus to Present at Leerink Swann Global Healthcare Conference investment picks
2013/2/19
Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter 2012 financial results after market close on Monday, March 4, 2013.
Sign-up for Santarus to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 4 investment picks
2013/2/27
Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.
Sign-up for Santarus to Present at March Investment Conferences investment picks
2013/3/18
Santarus, Inc. (NASDAQ: SNTS) today announced that results from its CORE II clinical study, one of two of the company’s pivotal Phase III clinical studies with UCERIS ™ (budesonide) extended release tablets in patients with ulcerative colitis, have been published online in the peer-reviewed journal Gut .
Sign-up for Santarus Announces Publication in Gut of Results from UCERIS (budesonide) European Pivotal Clinical Study investment picks
2013/3/26
http://media.marketwire.com/attachments/201303/58966_Santarus.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1000643&ProfileId=051205&sourceType=1 SAN DIEGO, CA --
Sign-up for Santarus to Host Investor and Analyst Day on April 11, 2013 investment picks
2013/4/17
Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RUCONEST ® (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). The safety and efficacy of RUCONEST for the treatment of HAE attacks were evaluated in a clinical program that included a Phase III randomized placebo-controlled study conducted under a Special Protocol Assessment agreement with the FDA.
Sign-up for Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA investment picks
2013/4/22
Santarus, Inc. (NASDAQ: SNTS) today announced that it will release first quarter 2013 financial results after market close on Monday, May 6, 2013.
Sign-up for Santarus to Hold First Quarter 2013 Financial Results Conference Call on May 6 investment picks
2013/5/6
Santarus, Inc. (NASDAQ: SNTS) , a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2013.
Sign-up for Santarus Reports First Quarter 2013 Financial Results investment picks
2013/5/3
Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T.
Sign-up for Santarus to Present at May and June Investment Conferences investment picks
2013/5/9
Santarus, Inc. (NASDAQ: SNTS) today announced a proposed secondary underwritten public offering of shares of its common stock.
Sign-up for Santarus Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder investment picks
2013/5/10
Santarus, Inc. (NASDAQ: SNTS) today announced the pricing of a secondary underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $18.25 per share.
Sign-up for Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder investment picks
2013/5/17
Santarus, Inc. (NASDAQ: SNTS) today announced that additional data from two pivotal clinical studies with UCERIS ® (budesonide) extended release tablets will be featured in two poster presentations at the Digestive Disease Week ® (DDW ® ) Meeting being held in Orlando, Fla.
Sign-up for Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting investment picks
2013/5/15
Santarus, Inc. (NASDAQ: SNTS) today announced the completion of a secondary underwritten public offering of 4,887,500 shares of its common stock, including 637,500 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriter.
Sign-up for Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Santarus, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Sanofi Adr  |  Next: ETFS Holding Sap AG